Forest, Merz Wrap Up Namenda Patent Litigation

Law360, New York (July 22, 2010, 6:20 PM EDT) -- Having reached a settlement with Mylan Pharmaceuticals Inc., Forest Laboratories Inc. and Merz Pharma GmbH & Co. KGaA now have deals in place to resolve all pending patent litigation over the lucrative Alzheimer's drug Namenda.

Mylan said its settlement and license agreements with Forest and Merz give it the right to sell memantine hydrochloride tablets, the generic formulation of Namenda, in the U.S. on Jan. 11, 2015, or perhaps earlier under certain circumstances.

Forest and Merz went on the legal warpath over Namenda in 2008, suing...
To view the full article, register now.